Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 2/20 | 1.00 |
| ▸ | GRM6 | O15303 | 2/20 | 1.00 |
| ▸ | GRM7 | Q14831 | 2/20 | 1.00 |
| ▸ | GRM4 | Q14833 | 2/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 1/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 1/20 | 1.00 |
| ▸ | GSR | P00390 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | GRIK1 | P39086 | 1/20 | 1.00 |
| ▸ | GRM5 | P41594 | 1/20 | 1.00 |
| ▸ | GRIA1 | P42261 | 1/20 | 1.00 |
| ▸ | GRIA2 | P42262 | 1/20 | 1.00 |
| ▸ | GRIA3 | P42263 | 1/20 | 1.00 |
| ▸ | SLC1A3 | P43003 | 1/20 | 1.00 |
| ▸ | SLC1A2 | P43004 | 1/20 | 1.00 |
| ▸ | SLC1A1 | P43005 | 1/20 | 1.00 |
| ▸ | GRIA4 | P48058 | 1/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 1/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 1/20 | 1.00 |
| ▸ | GRIK2 | Q13002 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutamic Acid SCHEMBL1554237 | 1.00 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL1332297 | 1.00 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL43222 | 1.00 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIN2D | |
| Glutamic Acid SCHEMBL2202 | 1.00 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL1332144 | 1.00 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL410241 | 1.00 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIN2D | |
| Glutamic Acid SCHEMBL5704264 | 1.00 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL1330566 | 1.00 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL1330917 | 1.00 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL931953 | 1.00 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250314666-A1 | DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDERS BASED ON AMINE CONTAINING METABOTYPES | STEMINA BIOMARKER DISCOVERY INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250027938-A1 | METABOLIC SIGNATURE FOR PREDICTION OF MUCOSAL INFLAMMATION AND MICROBIAL COMPOSITION | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-01-23 | — | — | US | disclosed |
| CN-117898432-B | Synbiotic composition and application thereof | 广东燕塘乳业股份有限公司 | 2024-11-19 | — | — | CN | disclosed |
| CN-117898433-B | Synbiotic composition and application thereof | 广东燕塘乳业股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118531029-A | Application of knockout aspA gene in improving L-phenylalanine yield | 河南省健康元生物医药研究院有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-117987431-A | Application of knock-out mhpA gene in improving L-phenylalanine yield | 河南省健康元生物医药研究院有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117898433-A | Synbiotic composition and application thereof | 广东燕塘乳业股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20240118291-A1 | DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDERS USING ALTERED RATIOS OF METABOLIC CONCENTRATIONS | STEMINA BIOMARKER DISCOVERY INC (US) | 2024-04-11 | — | — | US | disclosed |
| CN-116758975-B | Detection and identification method for preventing and treating Ling nan characteristic damp-heat syndrome effect of Liupu tea in phoenix state | 广东药科大学 | 2023-11-24 | — | — | CN | disclosed |
| CN-116758975-A | Detection and identification method for preventing and treating Ling nan characteristic damp-heat syndrome effect of Liupu tea in phoenix state | 广东药科大学 | 2023-09-15 | — | — | CN | disclosed |
| US-11241455-B2 | Methods of treating disease by metabolic control of T-cell differentiation | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2022-02-08 | — | — | US | disclosed |
| US-9673030-B2 | Computer readable storage mediums, methods and systems for normalizing chemical profiles in biological or medical samples detected by mass spectrometry | EMORY UNIVERSITY (US) | 2017-06-06 | — | — | US | disclosed |
| US-20110282587-A1 | COMPUTER READABLE STORAGE MEDIUMS, METHODS AND SYSTEMS FOR NORMALIZING CHEMICAL PROFILES IN BIOLOGICAL OR MEDICAL SAMPLES DETECTED BY MASS SPECTROMETRY | EMORY UNIVERSITY (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11241455-B2 | Methods of treating disease by metabolic control of T-cell differentiation | GOT1, IL17A, OGDH | GRM8 1661/4885GRM6 2132/4885GRM7 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.